<code id='A268FAC2F3'></code><style id='A268FAC2F3'></style>
    • <acronym id='A268FAC2F3'></acronym>
      <center id='A268FAC2F3'><center id='A268FAC2F3'><tfoot id='A268FAC2F3'></tfoot></center><abbr id='A268FAC2F3'><dir id='A268FAC2F3'><tfoot id='A268FAC2F3'></tfoot><noframes id='A268FAC2F3'>

    • <optgroup id='A268FAC2F3'><strike id='A268FAC2F3'><sup id='A268FAC2F3'></sup></strike><code id='A268FAC2F3'></code></optgroup>
        1. <b id='A268FAC2F3'><label id='A268FAC2F3'><select id='A268FAC2F3'><dt id='A268FAC2F3'><span id='A268FAC2F3'></span></dt></select></label></b><u id='A268FAC2F3'></u>
          <i id='A268FAC2F3'><strike id='A268FAC2F3'><tt id='A268FAC2F3'><pre id='A268FAC2F3'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:explore    Page View:8844

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In